Browse All
Displaying 6 - 6 of 6
Author:Cohen, Jeffrey Hauser, Stephen Cross, Anne Winthrop, Kevin Wiendl, Heinz Nicholas, Jacqueline Meuth, Sven Giacomini, Paul Sacca, Francesco Zielman, Ronald Das Gupta, Ayan Hu, Xixi Sullivan, Roseanne DeLasHeras, Virginia Kappos, Ludwig
Session Name:P8: MS Therapeutics 2
Topic:MS and Inflammatory Disease
Program Number:P8.004
Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR University of Muenster, Muenster, Germany, Muenster, Germany OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
